Danaher Co. (NYSE:DHR) Shares Purchased by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 2.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,382 shares of the conglomerate’s stock after acquiring an additional 84 shares during the period. Trueblood Wealth Management LLC’s holdings in Danaher were worth $940,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DHR. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC purchased a new stake in Danaher during the second quarter valued at about $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the first quarter worth about $30,000. MFA Wealth Advisors LLC purchased a new position in shares of Danaher in the second quarter worth approximately $51,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Danaher during the second quarter valued at approximately $51,000. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of recent analyst reports. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday. Wells Fargo & Company assumed coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Leerink Partners upped their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. UBS Group decreased their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, TD Cowen upped their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $287.28.

Danaher Trading Down 1.0 %

Danaher stock opened at $245.41 on Friday. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company’s fifty day moving average price is $269.52 and its two-hundred day moving average price is $260.35. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market capitalization of $181.77 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the firm posted $2.02 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 18.31%.

Insider Buying and Selling

In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,059 shares of company stock valued at $8,400,897. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.